Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials ; volume:17 ; number:1 ; day:4 ; month:4 ; year:2017 ; pages:1-13 ; date:12.2017
BMC neurology ; 17, Heft 1 (4.4.2017), 1-13, 12.2017
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
-
Abushouk, Abdelrahman Ibrahim
- Beteiligte Personen und Organisationen
-
Elmaraezy, Ahmed
Aglan, Amro
Salama, Reham
Fouda, Samar
Fouda, Rana
AlSafadi, Ammar M.
SpringerLink (Online service)
- DOI
-
10.1186/s12883-017-0850-1
- URN
-
urn:nbn:de:1111-201704226756
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Abushouk, Abdelrahman Ibrahim
- Elmaraezy, Ahmed
- Aglan, Amro
- Salama, Reham
- Fouda, Samar
- Fouda, Rana
- AlSafadi, Ammar M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Drug candidates in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Drug candidates in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Drug candidates in clinical trials for Alzheimer’s disease